Biosimilar user fee reauthorization negotiations are nearly completed, making the program the second of three drug and biologic-related programs ready to complete the first step toward another five-year extension.
A source with knowledge of the negotiations told Generics Bulletin sister publication the Pink Sheet that commitment letter language is...